Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 26;13(13):3739.
doi: 10.3390/jcm13133739.

Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes

Michelle Volovsky  1 , David B Seifer  1
Affiliations
Review

Current Status of Ovarian and Endometrial Biomarkers in Predicting ART Outcomes

Michelle Volovsky et al. J Clin Med. .

Abstract

This review evaluates the role of ovarian and endometrial biomarkers in predicting outcomes in assisted reproductive technology (ART). It highlights established ovarian biomarkers such as the anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH), alongside emerging ones like growth differentiation factor 9 (GDF9), bone morphogenetic protein 15 (BMP15), connexin, and granulosa cell gene profiles. Additionally, the paper explores endometrial biomarkers such as ERA, BCL6, and immune markers, as well as the potential for genomic and proteomic technologies in customizing implantation. It concludes that while many of these biomarkers show promise, their clinical integration requires rigorous research and validation to confirm their safety and utility in ART.

Keywords: ART; biomarkers; endometrial; outcomes; ovarian; predictor.

PubMed Disclaimer

Conflict of interest statement

D.B.S. received royalties from a licensing agreement between Rutgers Medical School/MGH and Beckman Coulter for the use of AMH in determining ovarian reserve. MV declares no conflicts of interest.

References

    1. Seifer D.B., MacLaughlin D.T., Christian B.P., Feng B., Shelden R.M. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril. 2002;77:468–471. doi: 10.1016/S0015-0282(01)03201-0. - DOI - PubMed
    1. Muttukrishna S., Suharjono H., McGarrigle H., Sathanandan M. Inhibin B and anti-Mullerian hormone: Markers of ovarian response in IVF/ICSI patients? BJOG Int. J. Obstet. Gynaecol. 2004;111:1248–1253. doi: 10.1111/j.1471-0528.2004.00452.x. - DOI - PubMed
    1. Lekamge D.N., Barry M., Kolo M., Lane M., Gilchrist R.B., Tremellen K.P. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod. Biomed. Online. 2007;14:602–610. doi: 10.1016/S1472-6483(10)61053-X. - DOI - PubMed
    1. Broer S.L., Mol B.W., Hendriks D., Broekmans F.J. The role of antimullerian hormone in prediction of outcome after IVF: Comparison with the antral follicle count. Fertil. Steril. 2009;91:705–714. doi: 10.1016/j.fertnstert.2007.12.013. - DOI - PubMed
    1. Majumder K., Gelbaya T.A., Laing I., Nardo L.G. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010;150:166–170. doi: 10.1016/j.ejogrb.2010.02.029. - DOI - PubMed

LinkOut - more resources